Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 17, 2023

BUY
$20.13 - $27.29 $55,075 - $74,665
2,736 Added 13.89%
22,435 $529,000
Q2 2023

Jul 28, 2023

BUY
$18.33 - $27.18 $361,082 - $535,418
19,699 New
19,699 $518,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.14B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Mach 1 Financial Group, LLC Portfolio

Follow Mach 1 Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mach 1 Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mach 1 Financial Group, LLC with notifications on news.